
Sign up to save your podcasts
Or


Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
By Bloomberg3.8
381381 ratings
Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.

974 Listeners

1,166 Listeners

2,182 Listeners

425 Listeners

971 Listeners

196 Listeners

1,037 Listeners

187 Listeners

69 Listeners

1,307 Listeners

64 Listeners

77 Listeners

30 Listeners

62 Listeners

5 Listeners

58 Listeners

233 Listeners

232 Listeners

68 Listeners

82 Listeners

77 Listeners

75 Listeners

87 Listeners

402 Listeners

18 Listeners

13 Listeners

7 Listeners

2 Listeners

115 Listeners

23 Listeners